Drug Database
Back to search

Netherlands· NL-0a929f118409

Blenrep 100 mg poeder voor concentraat voor oplossing voor infusie

A belantamab mafodotin product containing belantamab mafodotin, registered in Netherlands by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 12 of our 19 countries.

ATC L01FX15

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedBlenrep 100 mg poeder voor concentraa…ATCL01FX15REGISTER NO.NL-0a929f118409PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about belantamab mafodotinAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Belantamab mafodotin is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FX15 (belantamab mafodotin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search belantamab mafodotin products by name

Belantamab mafodotin · ATC L01FX15

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
BELANTAMAB MAFODOTIN
Manufacturer
GlaxoSmithKline Trading Services Limited
Country
Netherlands (NL)
ATC code
L01FX15
ATC class
Belantamab mafodotin
Defined daily dose
8.3 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/1948

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

58 interactions on record for belantamab mafodotin.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check belantamab mafodotin against other medicinesHow interaction checks work

Belantamab mafodotin · interactions on record

58 records

  • 28 severe
  • 30 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Belantamab mafodotin in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All belantamab mafodotin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Blenrep
  • Liechtenstein · Blenrep
  • Norway · Blenrep

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c78d9a07-b4d1-4d6a-aa97-40e2fe87fca2
GET /v1/drugs/c78d9a07-b4d1-4d6a-aa97-40e2fe87fca2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Belantamab mafodotin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133810",
  "excipients": [
    "CITROENZUUR 1-WATER (E 330)",
    "DINATRIUMEDETAAT 2-WATER",
    "POLYSORBAAT 80 (E 433)",
    "TREHALOSE (Alpha, Alpha-)  2-WATER",
    "TRINATRIUMCITRAAT 2-WATER (E 331)"
  ],
  "substances": [
    "BELANTAMAB MAFODOTIN"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/07/23",
  "procedure_number": "EMEA/H/C/006511",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1948",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about belantamab mafodotin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console